Treace Medical Concepts, Inc. TMCI
NASDAQ · United States · Health Technology
$4.39+0.06 (+1.39%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Treace Medical Concepts, Inc. (NASDAQ:TMCI) announced five-year ALIGN3D results on September 17, adding longer-term evidence for the Lapiplasty bunion-correction procedure. The final analysis included 137 of 173 treated patients, or approximately 79% of the original group. Reported radiographic recurrence was 0.8% when defined as a hallux valgus angle greater than 20 degrees and 5.3% using […]
PONTE VEDRA, Fla., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and other foot & ankle conditions, today announced the presentation of the results from three clinical studies at the American Orthopaedic Foot & Ankle Society (“AOFAS”) Annual Meeting in Seattle, Washington. The presentations include data on the milestone 5-year ALIGN3D® Lap
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.